|
[22]
|
Slovenia (1)
|
Not specifically stated.
|
30
|
Method of randomization unclear.
|
ESRD patients with subclavian or jugular single lumen catheters inserted as temporary blood accesses for HD expected to be used for at least 7 days.
|
3 ml of 4% trisodium citrate
|
A mixture of 1 ml (5000 U/ml) of unfractionated heparin and 2 ml of saline.
|
Catheter removal.
|
Not specified.
|
|
[23]
|
Belgium (1)
|
April 2000 - October 2000
|
19
|
Method of randomization unclear.
|
Chronic hemodialysis patients with a single lumen central venous catheter as permanent vascular dialysis access.
|
5% trisodium citrate
|
5000 U/ml heparin solution
|
Local/in-situ thrombolysis (bolus events for inadequate blood flow).
|
Not specified.
|
|
[24]
|
Canada (1)
|
December 2004 - June 2005
|
61
|
Randomization based on patient surnames.
|
All patients receiving chronic HD three times a week, 4 h/session, at the in-center Hemodialysis Unit with cuffed catheters as primary vascular access were eligible for the trial.
|
Prefilled 5 ml syringe containing 4% citrate (MEDXL, Montreal, Quebec, Canada).
|
1 ml of 10,000 U/ml heparin diluted to 5000 U/ml with normal saline
|
Patient survival, bacteremia rates, catheter removal, and local/in-situ thrombolysis.
|
Not specified.
|
|
[25]
|
United Kingdom (4)
|
6 mo. period
|
232
|
Open-label. Randomization was achieved through single-random number allocation.
|
ESRD patients with IJ CVCs (Bio-Flex TC), on HD > 90 days.
|
46.7% trisodium citrate.
|
5% heparin
|
Patient survival, bacteremia rates, catheter-related hospitalization rates, catheter replacement/exchange rates, use of urokinase.
|
Not specified.
|
|
[26]
|
Netherlands (10)
|
April 2001 - September 2002
|
291
|
Randomization by computer-generated random number list.
|
Patients >18 years, not admitted to the intensive care ward, with chronic or acute renal failure that required hemodialysis through a CVC. Only patients with a newly inserted, well-positioned CVC expected to be in use for 1 wk.
|
30% trisodium citrate
|
Unfractionated sodium heparin 5000 U/ml
|
Patient survival, bacteremia rates, catheter-related infection hospitalization rates, catheter removal rates, and catheter treatment with urokinase.
|
Not specified.
|
